Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination

Akopov, Sergey E.; Gabrielian, E.

doi:10.1007/bf00266344

Cited by 10 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human genetic studies have defined significant associations of PDE1A SNP with carotid intima–media thickness (Bautista Nino et al, 2015, Yan, 2015). Interestingly, vinpocetine also reduced vascular thrombosis after vascular injury in mice (Cai et al, 2012), which is consistent with previously reported effect of vinpocetine on antagonizing platelet aggregation (Akopov and Gabrielian, 1992). Furthermore, vinpocetine has been shown to attenuate high-fat diet-induced atherosclerosis in ApoE-deficient mice (Cai et al, 2013, Zhuang et al, 2013), as well as prevent atherosclerosis and calcification in rabbit atherosclerosis models (Yasui et al, 1989, Yasui et al, 1990).…”

Section: Vinpocetine and Vascular Diseasessupporting

confidence: 91%

An update on vinpocetine: New discoveries and clinical implications

Zhang

Yan

2018

European Journal of Pharmacology

120

View full text Add to dashboard Cite

Vinpocetine, a derivative of the alkaloid vincamine, has been clinically used in many countries for treatment of cerebrovascular disorders such as stroke and dementia for more than 30 years. Currently, vinpocetine is also available in the market as a dietary supplement to enhance cognition and memory. Due to its excellent safety profile, increasing efforts have been put into exploring the novel therapeutic effects and mechanism of actions of vinpocetine in various cell types and disease models. Recent studies have revealed a number of novel functions of vinpocetine, including anti-inflammation, antagonizing injury-induced vascular remodeling and high-fat-diet-induced atherosclerosis, as well as attenuating pathological cardiac remodeling. These novel findings may facilitate the repositioning of vinpocetine for preventing or treating relevant disorders in humans.

show abstract

Section: Vinpocetine and Vascular Diseasessupporting

confidence: 91%

An update on vinpocetine: New discoveries and clinical implications

Zhang

Yan

2018

European Journal of Pharmacology

120

View full text Add to dashboard Cite

show abstract

“…Several in vitro and in vivo studies have shown the inhibitory effects of calcium antagonists on platelet aggregation and secretion 1 , 2 , 3 , 4 . In particular, calcium antagonists inhibit platelet aggregation induced by combined agonists, such as epinephrine and serotonin, or subthreshold concentrations of arachidonic acid combined with platelet activating factor, adenosine diphosphate, or epinephrine 23 , 24 , 25 . In addition, some calcium antagonists have been proven to abolish the constrictor effects of aggregating platelets on aortic segments with disrupted endothelium 26 .…”

Section: Discussionmentioning

confidence: 99%

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: A cohort study

Zuccalà

Cocchi

Pahor

et al. 2000

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

Objective To assess the association between in‐hospital use of calcium antagonists and incident reduction in hemoglobin levels, as well as the impact of individual baseline risk for gastrointestinal bleeding on such an association. Methods The association between calcium antagonists and hemoglobin decrease >1.2 g/dL was examined in 6721 patients enrolled in a collaborative pharmacoepidemiology study who did not take calcium antagonists before admission and with baseline hemoglobin ≥12 g/dL. Among these participants, 1076 patients started taking calcium antagonists during their hospital stays. Demographic variables, comorbid conditions, medications, and objective tests that were associated with incident hemoglobin loss in separate age‐ and sex‐adjusted logistic regression models were examined as potential confounders in a summary model. Higher risk for gastrointestinal bleeding was defined by diagnosis, treatment for peptic disease, or both. Results Hemoglobin decrease was detected in 24% of participants who started treatment with calcium antagonists and in 19% of other patients (P < .0001). In addition, use of calcium antagonists was independently associated with increased probability of hemoglobin loss (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.03 to 1.45; P = .018) after adjusting for potential confounders. Treatment with calcium antagonists was associated with hemoglobin loss in patients with higher baseline risk for gastrointestinal bleeding (OR, 1.67; 95% CI, 1.26 to 2.22; P < .0001) but not among other participants (OR, 1.02; 95% CI, 0.82 to 1.25). Conclusion Starting treatment with calcium antagonists is associated with a reduction in hemoglobin levels during a hospital stay. However, the increased risk of hemoglobin loss seems to be limited to patients with diagnosis or symptoms of peptic disease. (Clin Pharmacol Ther 2000;67:314–22.) Clinical Pharmacology & Therapeutics (2000) 67, 314–322; doi:

show abstract

“…The effect of tirofiban on WB aggregation induced by a combination of agonists at subthreshold concentrations was measured over a specified time period (1,3,5,10,15, and 20 minutes). Thus, we assessed saline (control), ADP (1 μM), fib (0.5 g/L), and a combination of ADP (1 μM) plus fib (0.5 g/L).…”

Section: Whole Blood (Wb) Aggregationmentioning

confidence: 99%

“…To assess the effect of tirofiban on 5HT-induced aggregation, 5HT (5 μM) was added and aggregation assessed at several time points (1,3,5,10,15, and 20 minutes) as previously described. 21 Then WB was incubated with tirofiban (500 ng/mL) for 5 minutes and 5HT (5 μM) was added before measuring aggregation again.…”

Section: Whole Blood (Wb) Aggregationmentioning

confidence: 99%

“…Also, circulating levels of agonists (eg, 5HT or ADP) on their own may not have any effect on platelets but in combination may produce a synergistic effect (eg, aggregation, stimulating vascular smooth muscle proliferation, and inducing vasoconstriction in atheromatous coronary vessels). 15 We also investigated the effect of tirofiban on a combination of fib and ADP at subthreshold concentrations. Others have shown that optimal platelet aggregation occurs when using pairs of agonists (eg, ADP + epinephrine and epinephrine + collagen) even when each of the agonists is added to the other at subthreshold doses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation

Jagroop

Mikhailidis

2008

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

There is evidence linking raised plasma fibrinogen (fib) and platelet hyperactivity with vascular events. One way to inhibit platelets is to block the platelet membrane glycoprotein (GP) IIb/IIIa receptor, which binds circulating fib or von Willebrand factor and cross-links platelets at the final common pathway to platelet aggregation. Tirofiban is a potent and specific fib receptor antagonist, used in the treatment of unstable angina. The authors assessed the effect of tirofiban on spontaneous platelet aggregation (SPA), fib-induced, serotonin (5HT)-induced, and adenosine diphosphate (ADP)-induced aggregation in whole blood by calculating the percentage free platelet count. These various agonists were used alone and in combination. The authors also measured the effect of tirofiban on agonists-induced (ADP, 5HT) platelet shape change (PSC). The effect of fib on PSC was also evaluated in platelet-rich plasma using a high-resolution (0.07 fL) channelyzer. Tirofiban significantly inhibited SPA, fib (2, 4, 8 g/L), ADP, ADP + fib combination, and 5HT-induced aggregation. Tirofiban had no effect on agonist-induced PSC. There was no apparent change in platelet volume with fib. In conclusion, tirofiban does not appear to have an effect on PSC, an early phase of platelet activation. Tirofiban seems to be a nonspecific and an effective inhibitor of platelet aggregation (a later phase of platelet activation) in whole blood. The clinical significance of these findings remains to be established.

show abstract

Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination

Cited by 10 publications

References 10 publications

An update on vinpocetine: New discoveries and clinical implications

An update on vinpocetine: New discoveries and clinical implications

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: A cohort study

The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation

Contact Info

Product

Resources

About